HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dehydroretronecine-induced skin tumors in mice.

Abstract
Female Swiss mice susceptible to skin tumors received 6 sc injections and/or topical applications of dehydroretronecine, a metabolite of the pyrrolizidine alkaloid monocrotaline, and were observed for 15 months for tumor development. Of 92 animals examined, 63 had tumors at the site of application or injection; 47 of these had skin tumors, mainly basal cell and squamous cell carcinomas. These data indicate that dehydroretronecine is a proximate carcinogen capable of causing a high incidence of skin tumours in mice at the site of sc injection or topical application.
AuthorsW D Johnson, K A Robertson, J G Pounds, J R Allen
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 61 Issue 1 Pg. 85-9 (Jul 1978) ISSN: 0027-8874 [Print] United States
PMID276619 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Pyrrolizidine Alkaloids
  • Monocrotaline
  • dehydroretronecine
Topics
  • Administration, Topical
  • Animals
  • Carcinoma, Basal Cell (chemically induced, pathology)
  • Carcinoma, Squamous Cell (chemically induced, pathology)
  • Female
  • Injections, Subcutaneous
  • Mice
  • Monocrotaline (analogs & derivatives)
  • Neoplasms, Experimental (chemically induced)
  • Pyrrolizidine Alkaloids (administration & dosage, toxicity)
  • Skin Neoplasms (chemically induced, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: